SEC Form 4 · accession 0001394548-17-000027
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Chin
Director
Period of report
Oct 10, 2017
Accepted (ET)
Oct 10, 2017 · 5:45 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Oct 10, 2017 | A | 12,708 | $0.38 | A | 31,339 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Effective January 1, 2017, 33% of the cash retainer payments to our Board will be paid in unrestricted shares of the Company's common stock, delivered from the 2016 Incentive Plan and priced on the first trading day of the quarter.
- F2Represents the closing stock price of the Company's stock on the first trading day of the quarter.